Cardio Diagnostics Holdings, Inc.

CDIOW

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0001870144

None

No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $7.8M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	thin data, degenerate inputs not computable: dilution, short runway, distress, fortress balance sheet
Inputs computable	4 of 14
Graded from	filings received through Mar 13, 2026 230 days before the rescan; latest periodic filing 10-Q received Aug 7, 2026
Last close	$0.01 2026-08-26; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 13, 2026

"we," "us" or the "Company" refer to Cardio Diagnostics Holdings, Inc. References to our "management" or our "management team" refer to the officers and directors of Cardio Diagnostics Holdings, Inc. a series of products for major types of cardiovascular disease and associated co-morbidities, including coronary heart disease ("CHD"), stroke, heart failure and diabetes, by leveraging our Artificial Intelligence ("AI")-driven Multi-Omics Engine? (formerly known as our AI-Integrated Genetic-Epigenetic EngineTM). As a company, we aspire to give every American adult insight into their unique risk for various cardiovascular diseases.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 46.5						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(8.4%)	(6.6%)	46.5	805	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 34.1					
Twelve-month failure probability	not computable	0.07%			
firm-wide XBRL shares cannot be assigned to one ticker class					
Altman Z double-prime	(4.17)	(0.33)	51.3	751	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	9.79x	2.94x	17.0	832	2025-12-31
Growth and financing, sleeve percentile 36.1					
Revenue growth, three-year compound	not computable	10.1%			
current value must be positive and the base must exceed $100,000					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 3					
Reinvestment rate	not computable	37.1%			
required facts have no common fiscal period end					
Asset growth, three years	7.5%	2.1%	36.1	697	2025-12-31
Net share issuance, one year	not computable	2.5%			
firm-wide XBRL shares cannot be assigned to one ticker class					

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	4 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-08-26 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(18.1%)	7.7%	32
Distance from 52-week high	(81.5%)	(27.7%)	8
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.27	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.41)	(0.14)	32

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$0
Operating cash flow, four quarters	-$5.7M
Months of runway	not finite
Days since last periodic filing	83 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	$22

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$6.5M	2025-12-31	2026-03-13	10-K	26-000023
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$5.7M	2025-12-31	2026-03-13	10-K	26-000023
3	assets	us-gaap:Assets	$7.8M	2025-12-31	2026-03-13	10-K	26-000023
4	assets	us-gaap:Assets	$10.6M	2024-12-31	2026-03-13	10-K	26-000023
5	current assets	us-gaap:AssetsCurrent	$5.9M	2025-12-31	2026-03-13	10-K	26-000023
6	current liabilities	us-gaap:LiabilitiesCurrent	$604,839	2025-12-31	2026-03-13	10-K	26-000023
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$29.2M	2025-12-31	2026-03-13	10-K	26-000023
8	operating income	us-gaap:OperatingIncomeLoss	-$6.5M	2025-12-31	2026-03-13	10-K	26-000023
9	book equity	us-gaap:StockholdersEquity	$7.0M	2025-12-31	2026-03-13	10-K	26-000023
10	liabilities	us-gaap:Liabilities	$793,061	2025-12-31	2026-03-13	10-K	26-000023
11	interest expense	us-gaap:InterestExpense	$14,801	2025-12-31	2026-03-13	10-K	26-000023
12	revenue	us-gaap:Revenues	$14,825	2025-12-31	2026-03-13	10-K	26-000023
13	revenue	us-gaap:Revenues	$34,890	2024-12-31	2026-03-13	10-K	26-000023
14	revenue	us-gaap:Revenues	$17,065	2023-12-31	2025-03-20	10-K	25-000428
15	revenue	us-gaap:Revenues	$950	2022-12-31	2024-04-01	10-K	24-000480
16	assets	us-gaap:Assets	$4.5M	2023-12-31	2025-03-20	10-K	25-000428
17	assets	us-gaap:Assets	$6.2M	2022-12-31	2024-04-01	10-K	24-000480

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.